FDA Clears Third Wave Invader Pharmacogenetic Test
This article was originally published in The Gray Sheet
Executive Summary
Oncologists will be able to use Third Wave Technologies' Invader UGT1A1 molecular assay to select appropriate doses of Pfizer's chemotherapy drug Camptosar (irinotecan)for colorectal cancer, following 510(k) clearance Aug. 22
You may also be interested in...
Hologic Gains HPV Test Technology In $580 Million Third Wave Purchase
Hologic's purchase of molecular diagnostics firm Third Wave Technologies for $580 million provides a platform for near-term entry into the expanding, $200 million U.S. market for human papillomavirus testing
Hologic Gains HPV Test Technology In $580 Million Third Wave Purchase
Hologic's purchase of molecular diagnostics firm Third Wave Technologies for $580 million provides a platform for near-term entry into the expanding, $200 million U.S. market for human papillomavirus testing
Warfarin Labeling Change: Genetic Test Firms Anxiously Await FDA Action
Genetic test makers are lining up in anticipation of an FDA label change for the blood thinner warfarin that could significantly expand the market for companion diagnostics. They might still have a while to wait